CellsBin
PrivateLast Round
Series A
Sep 22, 2026
Momentum
Top 5%
of companies Caplight tracks
Company Overview
CellsBin operates in Healthcare & Life Sciences and is based in Branford, Connecticut. Its latest recorded funding round was a Series A round in September 2026.
CellsBin is a biotechnology company that develops a Rare-Cell Intelligence™ platform integrating microfluidics, multimodal imaging, single-cell analysis, and artificial intelligence to detect and monitor rare cells for precision medicine applications.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical Devices, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CellsBin Comparables
Compare CellsBin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TellBio Inc. | 86% | |
| Vortex Biosciences | 86% | |
| RareCyte | 81% |
For institutional investors. Book with your work email.
CellsBin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 22, 2026 | ||||
| Accelerator | Dec 1, 2025 | ||||
| Seed | Sep 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CellsBin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed |
| 108 BioCapital | Series A |
| Endless Frontier Labs | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2026
Led by 108 BioCapital
- Jul 26, 2026
Monthly visitors grew 219% MoM, reaching 2.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 28, 2026
CellsBin Inc. receives a $2.1M grant from the National Cancer Institute to advance a multiple myeloma blood test in New York on Oct 28th '26.
- attends_eventOct 27, 2026
CellsBin Inc. presents early myeloma results at the 2024 American Society of Hematology Annual Meeting.
- increases_headcount_bySep 22, 2026
On Sep 22nd '26, CellsBin Inc.'s Series A funding supports plans to add 6 jobs across Branford and New Haven, Connecticut, for production scale, a broader clinical footprint, commercialization, and team growth.
For institutional investors. Book with your work email.
CellsBin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CellsBin's valuation, stock price, and market status.
Is CellsBin a public or private company?
CellsBin is a private company.
What is the current stock price of CellsBin?
CellsBin is a private company, so its shares have no public market price. Caplight tracks CellsBin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CellsBin worth (valuation)?
Valuation information for CellsBin is not publicly available.
Can I buy CellsBin stock?
CellsBin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CellsBin's last funding round?
CellsBin's most recent funding round was Series A on September 22, 2026.
Who are the main investors in CellsBin?
Key investors in CellsBin include 108 BioCapital.
Will CellsBin IPO soon?
No public IPO plans have been announced for CellsBin.
How can I track CellsBin secondary market activity?
Caplight tracks bids, offers, and trades in CellsBin's shares on secondary markets.